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Abstract 
 
The natural flavonoid fisetin (3,3’,4’,7-tetrahydroxyflavone) has shown antitumour activity 25 
but its administration is complicated by its low water solubility. Our aim was to incorporate 
fisetin into a nanoemulsion to improve its pharmacokinetics and therapeutic efficacy. 
Solubility and emulsification tests allowed to develop an optimal nanoemulsion composed of 
Miglyol
®
 812 N / Labrasol
®
 / Tween
®
 80 / Lipoid E80
®
 / water 
(10%/10%/2.5%/1.2%/76.3%). The nanoemulsion had an oil droplet diameter of 153  2 nm, 30 
a negative zeta potential (-28.4  0.6 mV) and a polydispersity index of 0.129. The 
nanoemulsion was stable at 4°C for 30 days, but phase separation occurred at 20°C. 
Pharmacokinetic studies in mice revealed that the fisetin n noemulsion injected intravenously 
(13 mg/kg) showed no significant difference in systemic exposure compared to free fisetin. 
However, when the fisetin nanoemulsion was administered intraperitoneally, a 24-fold 35 
increase in fisetin relative bioavailability was noted, compared to free fisetin. Additionally, 
the antitumour activity of the fisetin nanoemulsion in Lewis lung carcinoma bearing mice 
occurred at lower doses (36.6 mg/kg) compared to free fisetin (223 mg/kg). In conclusion, we 
have developed a stable nano mulsion of fisetin and have shown that it could improve its 
relative bioavailability and antitumour activity. 40 
 
Keywords: Nanoemulsion, flavonoids, fisetin, pharmacokinetics, bioavailability, antitumor 
activity 
 
45 
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1. Introduction 
Among the plant-derived compounds that have been linked to the chemoprevention 
and treatment of cancer, the flavonoids occupy a special place due to their abundance in 
human food and their relative non toxicity (Havsteen, 2002; Lopez-Lazaro, 2002; Middleton, 
Jr. et al., 2000; Surh, 2003).  50 
In a program aimed at finding new antiangiogenic agents in the flavonoid family, we 
have recently identified the natural flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) as an 
interesting lead that can stabilize endothelial cells in vitro at non cytotoxic concentrations 
(Touil et al., 2009). Fisetin is found in several fruits, vegetables, nuts and wine (Arai et al., 
2000; Kimira et al., 1998) and displays a variety of biological effects including antioxidant, 55 
anti-inflammatory (Park et al., 2007; Woodman and Chan, 2004), anti-carcinogenic and in 
vitro anti-angiogenesis (Fotsis et al., 1997). Fisetin has been shown to inhibit several 
molecular targets, including cyclin-dependent kinases (Lu et al., 2005a; Lu et al., 2005b; Sung 
et al., 2007), DNA topoisomerases I and II (Constantinou et al., 1995; Olaharski et al., 2005), 
urokinase (Jankun et al., 2006), actin polymerization (Böhl et al., 2007), and androgen 60 
receptor signalling (Khan et al., 2008).  
In vivo, fisetin has recently been shown to possess interesting anticancer activity in 
mice bearing lung carcinoma (Touil et al., 2011), prostate tumours (Khan et al., 2008), and 
human embryonal carcinoma (Tripathi et al., 2011). Its in vivo mechanism of action appears 
rather complex and includes antiangiogenic, antiandrogenic and anti-metastatic activities 65 
(Chien et al., 2010; Khan et al., 2008; Touil et al., 2011; Tripathi et al., 2011). 
Despite its highly interesting properties for cancer therapy, fisetin administration in 
vivo remains problematic partly due to its poor water solubility (Guzzo et al., 2006; Mignet et 
al., 2012). Fisetin bioavailability must therefore be significantly improved in order to 
optimize its delivery to tumours after in vivo administration. Although the design of suitable 70 
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molecular carriers for flavonoids is an area of intense research, solutions are still far from 
being developed for therapy, and suitable molecular carriers for flavonoids have yet to be 
designed and tested (Leonarduzzi et al., 2010). To do so, we therefore chose to formulate 
fisetin into nanoemulsion in order to hopefully achieve a better bioavailability. 
Nanoemulsions represent good vehicles to formulate hydrophobic active molecules 75 
(Sarker, 2005). For example, nanoemulsions are widely used for parenteral administration of 
lipids, and have also been employed for intravenous administration of anticancer drugs like 
paclitaxel (Kan et al., 1999) and chlorambucil (Ganta et al., 2008). Also noteworthy, 
nanoemulsion has also been recently reported to contribute to the in vivo increase in efficacy 
of anticancer drugs, e.g., dacarbazine (Tagne et al., 2008) and camptothecin (Han et al., 80 
2009).  
The aim of the present study was therefore to design and characterize a nanoemulsion 
of fisetin that could be suitable for parenteral administration. We also evaluated the fisetin 
nanoemulsion pharmacokinetics after intravenous (i.v.) or intraperitoneal (i.p.) administration 
in mice, and determined its relative i.p. bioavailability compared to the i.p. administration of 85 
the free fisetin. Finally, the antitumour activity of the fisetin nanoemulsion was compared to 
the administration of free fisetin in Lewis lung carcinoma bearing mice.  
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2. Materials and methods 
 90 
2.1. Materials 
 
Fisetin (98% purity) was purchased from Shanghai FWD Chemicals Limited 
(Shanghai, China). The various purified oil phases were provided by the following 
companies: soybean oil (Société Industrielle des Oléagineux, Saint Laurent Blangy, France); 95 
carthame oil, ethyl oleate and n-capric acid (Sigma-Aldrich, Saint Quentin Fallavier, France); 
Miglyol
®
 812 N and Imwitor
®
 742 (Sasol Witten, Germany); Captex
®
 355 and Capmul
®
 PG-8 
(Abitec, Janesville, WI, USA); Labrafac lipophile WL 1349
®
 (Gattefossé, Saint Priest, 
France); triacetin (VWR Fontenay-sous-Bois, France).  
The surfactants were purchased from the following companies: egg lecithin containing 100 
82.3% phosphatidylcholine (Lipoid E80
®
, Lipoid GmbH Ludwigshafen, Germany); 
polysorbate 80 (Tween 80), sorbitan trioleate (Span 85®), polyoxyethylene glycol 2000 
monostearate (Myrj
®
 52) (Uniquema, Everberg, Belgium); polyoxyethylenated ricin oil 
(Cremophor EL
®
, BASF, Ludwigshafen, Germany) ; vitamin E TPGS (Eastman Chemical 
B.V., Paris, France); a mixture of glycerides and esters of PEG-8 (Labrasol
®
), a mixture of 105 
glycerides and esters of PEG 300 (Labrafil M 1944 CS
®
) (Gattefossé Saint Priest, France); 
glycerol monocaprylocaprate (Capmul MCM
®
, Abitec, Janesville, WI, USA). Glycerol was 
purchased from Labosi (Paris, France). Sterile water for injection was from Fresenius-Kabi 
(Sèvres, France). Sodium hydroxide 0.1 N was from Carlo Erba Reactif SDS (Peypin, 
France).  110 
The other chemicals used for drug dissolution, plasma preparation and HPLC analysis 
were the following: methanol, acetonitrile, perchloric acid (Carlo Erba Reactif SDS, Peypin, 
France); DMSO, PEG 200, morin, phosphate buffer (pH 7.4) and mouse serum (Sigma-
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Aldrich, Saint Quentin Fallavier, France). All other chemicals were of pharmaceutical grade 
or of the highest analytical purity available. 115 
 
2.2. Fisetin solubility studies 
 
Fisetin solubility was assessed according to the approached solubility method (Mulak 
and Cotty, 1975). Fisetin solubility was first separately assessed in different oil phases and 120 
surfactants, and thereafter in various mixtures of oil/surfactant (Tables 1-3). Increasing fisetin 
concentrations were introduced in the various phases under agitation and heating at 60  2°C 
until a precipitate was observed. The solubility was determined after cooling at room 
temperature.  
 125 
2.3. Nanoemulsion preparation 
 
Fisetin was dissolved in several fractions in a mixture of Labrasol
®
/Tween
®
 80 heated 
at 60  2°C under sonication (Sonifier® 450, Branson, Danbury, CT, U.S.A.). This mixture 
was added to the oil phase (Miglyol
®
 812) in which lecithin (Lipoid E80
®
) has previously 130 
been dispersed by heating. Aqueous and oil phases have been heated at 70  2°C thereafter. 
Emulsification was accomplished by phase inversion (Becher, 1965), i.e., the aqueous phase 
was added to the oil phase. The mixture was then submitted to a high shear mixer 
(Ultraturrax
®
 T25 , Ika, Staufen, Germany) for 10 min at 21,500 rpm (set at 5) that allowed 
the formation of a crude emulsion. An additional 15 min sonication in the cold of the previous 135 
emulsion using a Sonifier
®
 450 set at 90% and output 3 allowed to obtain a submicron 
emulsion. For intravenous (i.v.) and intraperitoneal (i.p.) administration, sodium hydroxide 
0.1 N was used to adjust pH to 7.0 and glycerol 2.25% was added to adjust tonicity. Two 
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methods of sterilization were investigated: steam sterilization using 120°C, 15 minutes cycle 
and filtration through a 0.22 µm filter. 140 
 
2.4. Nanoemulsion characterization and stability studies 
 
Nanoemulsions were visually inspected for eventual creaming, coalescence, phase 
separation and/or precipitation. After dilution (1/1000) in water, the mean droplet size, size 145 
distribution, the zeta potential (), and the polydispersity index (PDI) were determined using a 
Zetasizer Nano ZS (Malvern Instruments, Orsay, France). The PDI reflects the polydispersity 
of the emulsion ranging from 0 to 1, with lower values indicating a more monodispersed 
suspension. pH was determined using a pH meter 210 (MeterLab, Copenhagen, Denmark). A 
short term stability of the optimized formulations over a period of 30 days was accomplished 150 
at room temperature (+20  2°C) and at +4°C by evaluating the above mentioned parameters. 
Measurements were performed in triplicate.  
For the determination of the fisetin concentration, nanoemulsions were diluted 
(1/2000) in methanol, vortexed, and 100 µL were injected onto a reversed-phase HPLC 
system (Shimadzu CLASS-VP
®
, version 5.3), equipped with an octadecylsilane column 155 
(Beckman Ultrasphere ODS, 5 µm; 4.6  250 mm) thermostated at 20°C, and a UV detector 
set at 360 nm. The mobile phase was composed of 25% acetonitrile and 75% acidified water 
(2% v/v glacial acetic acid), at a flow rate of 1 mL/min. In these conditions the retention time 
of fisetin was 8 min. The area of the fisetin peak was reported to a calibration curve to 
determine the concentration of fisetin. Calibration curves were linear with correlation 160 
coefficients near unity. 
 
2.5. Effect of fisetin nanoemulsion on endothelial cells 
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Immortalized human endothelial cells (EAhy 926) (Edgell et al., 1983) were grown in 165 
DMEM containing 2 mM L-glutamine, 10% foetal bovine serum, 100 U/mL penicillin and 
100 µg/mL streptomycin (37°C, 5% CO2). Cells were plated onto 96-well plates at 5000 cells 
per well in 100 µL of culture medium. The fisetin-free nanoemulsion or the fisetin 
nanoemulsion were added to the cells for a 2 h exposure time, and the cell morphology was 
assessed under microscopy at a magnification of X100 (Nikon Diaphot, Nikon Corp. Japan). 170 
 
2.6. Fisetin pharmacokinetics in mice 
 
2.6.1. Mice and treatments 
Female 8 weeks old C57BL/6J mice (body weight 18-22 g), were purchased from 175 
Janvier (Le Genest-St-Isle, France). After an overnight fasting period, mice were administered 
the various treatments as described hereafter. For the intravenous (i.v.) administration into the 
tail vein, 21 mice received the free fisetin formulated in 20% DMSO, 20% PEG 200 and 60% 
saline at a final concentration of 1.3 mg/mL (hereafter referred as “free fisetin”). The total 
volume injected i.v. was 200 µL for a 20 g mouse, which corresponds to a volume of DMSO 180 
of 40 µL. It should be noted that an undiluted DMSO volume of 50 µL can be administered 
safely i.v. to mice without toxicity (Willson et al., 1965), and that in our studies, the final 
DMSO dose per mouse corresponds to 40 µL (for a 20 g mouse), which was further diluted in 
saline and injected slowly over 1 minute. We did not encounter any acute mortality using this 
formulation in our studies. 185 
A second group of 21 mice received the fisetin nanoemulsion in a final volume of 50 
µL, previously sterilized by filtration through 0.22 µm filters. The fisetin dose was 13 mg/kg 
for the free fisetin or its nanoemulsion. Mice were sacrificed at 5, 10, 15, 30 min, 1, 2, 4 h, the 
Page 10 of 40
Ac
ce
pte
d M
an
us
cri
pt
 9 
blood was obtained by cardiac puncture onto heparinized syringes, centrifuged (10,000  g, 
10 min), and the harvested plasma was kept frozen at -20°C until HPLC analysis. For the 190 
intraperitoneal (i.p.) administration, the free fisetin (prepared as described above for the i.v. 
route) was injected at the maximum tolerated dose by this route (223 mg/kg). The fisetin 
nanoemulsion dose was 112.5 mg/kg corresponding to an injected volume of 450 µL i.p. 
Three mice per time point were sacrificed at 0, 0.25, 0.5, 1, 2, 4, 8, 15 and 24 h to harvest the 
blood by cardiac puncture (heparinized syringe). Plasma was obtained by centrifugation 195 
(10,000  g, 10 min), and frozen at -20°C until HPLC analysis. All animal experiments have 
been carried out in accordance with institutional and French regulations concerning the 
protection of animals, and with the European Commission regulations.  
 
2.6.2. Determination of fisetin concentration in plasma 200 
Fisetin concentration in plasma was determined by HPLC as followed: to 100 µL of 
plasma was added 60 µL of a morin methanolic solution at 0.5 mg/mL (internal standard), and 
200 µL of cold acidified methanol (methanol:perchloric acid 70%, 200:1, v:v) to precipitate 
proteins. After vortexing for 5 min the samples were kept on ice for 15 min, and centrifuged 
at 10,000  g at 4°C. The supernatant (100 µL) was injected onto a reversed-phase HPLC 205 
system as described above with the UV detector set at 360 nm. The ratio of the area of the 
fisetin peak divided by the internal standard peak area was reported to a calibration curve to 
determine the concentration of fisetin. Calibration curves were linear with correlation 
coefficients near unity. The quantification limit of the system was 0.1 µg/mL. 
 210 
2.6.3. Pharmacokinetic parameters determination 
The following non compartmental pharmacokinetic parameters were calculated using 
standard methods (Gibaldi and Perrier, 1982): maximum concentration (Cmax) extrapolated to 
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time zero for the i.v. route; area under the plasma concentration versus time curve from time 
zero to the time of the last measurable concentration (AUC0-t) calculated by the trapezoidal 215 
method; terminal half-life = ln 2/Kel, where Kel is the terminal elimination rate constant. The 
mean residence time (MRT) was calculated as the AUMC/AUC, where AUMC is the area 
under the first moment curve. Clearance was calculated as the dose/AUC, and the volume of 
distribution Vss as the CLMRT. The mean absorption time (MAT) after i.p. administration 
was calculated as the MRTi.p. minus MRTi.v. (Gibaldi and Perrier, 1982). Relative 220 
bioavailability (F REL) comparing the free fisetin and its nanoemulsion for the same route of 
administration was determined by the following formula: F REL = (AUC NE x dose FREE)/(AUC 
FREE x dose NE).  
 
2.7. Evaluation of antitumour activity in mice 225 
Female 8 weeks old C57BL/6J mice (body weight 18-22 g) (Janvier, Le Genest-St-
Isle, France) were used for antitumour evaluation. Lewis lung tumour fragments (about 2 mm 
diameter) were implanted subcutaneously (s.c.) bilaterally into mouse flanks using a 12 gauge 
trocar. Four days after tumour implantation, the mice were submitted to the following i.p. 
treatments (4 mice per group) for 12 consecutive days (day 4 to 15): 4 control mice received a 230 
fisetin-free nanoemulsion; 4 mice received the fisetin nanoemulsion corresponding to 18.3 
mg/kg of fisetin; and, 4 mice were injected the fisetin nanoemulsion at 36.6 mg/kg. Tumour 
growth was assessed using caliper bi-dimensional measurements (in mm) and the tumour 
volume (mm
3
) was calculated according to the following formula: (width 
2
  length/2).  
 235 
2.8. Statistical analysis 
 Data are presented as the mean  SEM. Comparison between tumour volumes was 
assessed by the Student t test. 
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3. Results 240 
3.1. Fisetin solubility in various solvents 
 
Table 1 presents the solubility of fisetin in various solvents. Fisetin was not soluble in 
water (<1 mg/g) and was weakly soluble in ethanol (<14 mg/g). Fisetin was also found 
weakly soluble for all the oil phases tested, with a maximum solubility value < 6 mg/g for 245 
triacetin and < 5 mg/g for propylene glycol monocaprylate. 
Table 2 shows fisetin solubility in frequently used surfactants. In lipophilic surfactants 
(low HLB value), fisetin solubility was low, whereas its solubility was markedly increased in 
hydrophilic surfactants with high HLB values. The best surfactant was found to be Labrasol
®
 
which could solubilize up to 54 mg/g of fisetin.  250 
Finally, the solubility values of fisetin using several combinations of oils and 
surfactants in various proportions are presented in Table 3. It was found that the mixture 
composed of Tween
®
 80 and Labrasol
®
 (20/80) could solubilize fisetin most efficiently up to 
a maximal concentration of 45 mg/g. 
 255 
3.2. Development of a fisetin nanoemulsion 
 
3.2.1. Emulsification apacity 
Several nanoemulsion formulations were thereafter tested for their emulsification 
capacity and 3 cases could be observed, as follows (Table 4): a) no emulsification was 260 
obtained for certain formulations lacking Lipoid E80 (e.g., formulations 3 to 7) or 
containing soybean oil and Capmul MCM, as in formulation 2; b) formation of a 
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nanoemulsion was observed for formulations 1, 8 and 9; c) and, formulation 10 allowed the 
formation of a clear solution. 
 265 
3.2.2. Fisetin incorporation into nanoemulsion formulations 
We have next evaluated the maximum quantity of fisetin that could be incorporated 
into each nanoemulsion (formulations 1, 8, 9), or solution (formulation 10). Table 4 shows 
that formulation 1 could incorporate only 1 mg/g of fisetin, whereas formulations 8 and 9 
allowed the incorporation of 5 mg/g of the flavonoid. These formulations were found visually 270 
stable on day 1. Although formulation 10 allowed to solubilize up to 16 mg/g of fisetin due to 
its higher content in Labrasol
®
 and Tween
®
 80, it was unfortunately found to precipitate on 
day 1 for concentrations of 8 and 16 mg/g, but was found stable for a fisetin concentration of 
4 mg/g.  
 275 
3.2.3. Choice of final fisetin nanoemulsion formulation 
Considering the above results, formulations 8 and 9 were therefore considered a good 
compromise between fisetin content and nanoemulsion stability. These formulations were 
further tested for their particle diameter and polydispersity index (PDI) and it was observed 
that preparation 8 containing soybean oil yielded a nanoparticle diameter of 323  2 nm with 280 
a PDI of 0.153, whereas preparation 9 containing Miglyol 812 N showed a nanoparticles 
diameter of 146  3 nm and a PDI of 0.015. Formulation 9 was therefore chosen for further in 
vitro and in vivo testing because of its good fisetin content, its nanoparticle size and low PDI 
value. The final composition of nanoemulsion 9 containing 5 mg/ml of fisetin was therefore 
as follows: Miglyol 812 N (10%), Labrasol® (10%), Tween® 80 (2.5%), Lipoid E80® 285 
(1.2%), glycerol (2.25%), NaOH (0.1N) to adjust to pH 7, water to 100%. 
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3.3. Stability of the fisetin nanoemulsion 
 
We next performed short term stability studies of the fisetin nanoemulsion 290 
(preparation 9) over a period of 30 days at room temperature (20°C) and at 4°C (Table 5) by 
evaluating particle diameter, pH, zeta potential and the PDI. 
Droplet size of nanoemulsion 9 stored at 20°C increased markedly as a function of 
time until phase separation occurred on day 30, whereas for the 4°C storage condition, 
particle diameter remained relatively stable for the 30 day examination period. A slight 295 
decrease in pH was noted at both storage temperatures. For the zeta potential, negative values 
were observed and remained stable over 30 days for the 4°C storage condition. The PDI 
presented an important increase over time at 20°C, whereas it was found stable and relatively 
low at 4°C. In order to be administered via parenteral routes, we also checked if the 
nanoemulsion could sustain standard steam sterilization conditions (121°C for 15 min) but 300 
this resulted in phase separation. However, sterilization of nanoemulsion 9 has been 
successfully carried out using a 0.22 µm filter with preservation of homogeneity and size 
characteristics. 
 
3.4. Effect of fisetin nanoemulsion on endothelial cells 305 
 
Free fisetin has been reported to exert a distinct morphological effect on endothelial 
cells that is characterized by the rapid development of pseudopods at non cytotoxic 
concentrations (Touil et al., 2009). We therefore tested if the fisetin nanoemulsion 
(preparation 9) could exert the same morphological effects on Eahy 926 endothelial cells to 310 
verify if the active principle is indeed released from the pharmaceutical preparation. Figure 1-
A depicts control endothelial cells exposed to 1% DMSO which show typical cobblestone 
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appearance, whereas exposure to free fisetin led to the expected pseudopods formation 
(Figure 1-B). Endothelial cells exposed to control nanoemulsion without fisetin resemble 
normal control endothelial cells (Figure 1-C), whereas the pseudopods are indeed observed in 315 
the cells exposed to the fisetin nanoemulsion (Figure 1-D). This observation indicates that 
fisetin is indeed released from the nanoemulsion and can exert similar morphological effects 
as the free fisetin on endothelial cells. 
 
3.5. Fisetin nanoemulsion pharmacokinetics in mice 320 
 
The developed fisetin nanoemulsion (preparation 9) was next administered in vivo to 
evaluate its pharmacokinetics in mice. We first examined the intravenous route (i.v.) by 
injecting the free fisetin formulation or its nanoemulsion at a dose of 13 mg/kg. We noted a 
very similar pharmacokinetic profile between the two formulations with plasma 325 
concentrations versus time curves almost superimposable (Figure 2). Indeed, similar 
pharmacokinetic parameters in terms of Cmax, AUC and terminal half-life were observed for 
both formulations (Table 6). The i.v. route administration of the fisetin nanoemulsion was 
however found relatively toxic, because we noted a mortality rate of 3/21 mice (14%), 
apparently due to the rapid administration. 330 
 In order to avoid the acute toxicity of the i.v. administration, we next explored the 
intraperitoneal (i.p.) route. For the fisetin nanoemulsion, a comparison of its pharmacokinetics 
after i.p. administration with the free fisetin injected by the same route is presented in Figure 
3. Compared to the i.p. administration of the free fisetin, it can be seen that the injection of the 
fisetin nanoemulsion led to a significant increase in fisetin plasma concentrations, even at a 335 
fisetin nanoemulsion dose (112.5 mg/kg) half that of the free fisetin dose (223 mg/kg). The 
pharmacokinetic parameters presented in Table 6 indicate that not only the maximum plasma 
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concentrations reached were higher for the nanoemulsion, but the relative bioavailability was 
24-fold higher compared to the free fisetin. This increase in bioavailability with the 
nanoemulsion appears to be due to a faster absorption with this drug formulation as shown by 340 
a shorter mean absorption time (MAT) of 1.97 h compared to 5.98 h for the free fisetin. It is 
also noteworthy that following the i.p. administration of the fisetin nanoemulsion, no 
mortality was observed. 
 
3.6. Fisetin nanoemulsion antitumour activity in mice 345 
 
We were next interested to evaluate the antitumour activity of the developed fisetin 
nanoemulsion (preparation 9) in Lewis lung carcinoma bearing mice. A group of 4 control 
mice received the empty nanoemulsion and 2 other groups of 4 mice received the fisetin 
nanoemulsion at an equivalent dose of fisetin of 18.3 and 36.6 mg/kg administered i.p. for 12 350 
days starting on day 4 post tumour implantation. Results depicted in Figure 4 show that the 
fisetin nanoemulsion can significantly inhibit tumour growth in a dose-dependent manner, 
even at these relatively low dose levels of fisetin.  
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4. Discussion 355 
 
The main objectives of this study was to develop a nanoemulsion of the hydrophobic 
flavonoid fisetin, determine its pharmacokinetics in mice, and evaluate its anticancer activity 
in vivo. The first problems encountered were the low fisetin solubility in the classical oil 
phases usually employed in formulation, e.g., soybean oil or medium chain triglycerides (Date 360 
and Nagarsenker, 2008). The best solubility was observed with triacetin, a short chain 
triglyceride composed of triester of glycerol and acetic acid. However, triacetin does not 
exhibit remarkable emulsifying properties (Poullain-Termeau et al., 2008). Fisetin was also 
found weakly soluble in lipophilic surfactants, but was more soluble in hydrophilic 
surfactants. As a matter of fact, the maximum solubility was observed with Labrasol
®
, a 365 
mixture of triglycerides and polyethylene glycol esters possessing a hydrophilic-lipophilic 
balance of 14. We did not observe any synergistic effect between the oil phase and surfactant, 
be it hydrophilic or lipophilic. Hence, the fisetin low solubility in lipid phases leads to a weak 
association of the active principle in this phase and therefore requires more solubilising 
surfactant, as previously reported for a nanoemulsion of carbamazepine (Kelmann et al., 370 
2007). We finally found that the best mixture was the one composed of Labrasol
®
/Tween
®
 80 
which allowed to achieve an acceptable fisetin concentration of 5 mg/ml. 
Although Labrasol
®
 has already been employed in injectable preparations (Nornoo et 
al., 2008), no standard preparation has been developed so far, to our knowledge, with this 
proprietary formulation. Labrasol
®
 is mostly used in auto-emulsifying systems for oral 375 
administration (Kommuru et al., 2001) and it has been shown to increase oral absorption of 
hydrophilic drugs, e.g., gentamicin (Hu et al., 2001). Available toxicity data on Labrasol
®
 
show that it is relatively non toxic when given orally to rats with a LD50 of 22 g/kg (Gad et 
al., 2006). However, acute toxicity data are not available for the intravenous or intraperitoneal 
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routes. In our experiments, a mortality rate of 14% was noted for the i.v. route, whereas no 380 
mortality was observed for the i.p. route. The other components of the nanoemulsion are not 
likely to contribute to acute toxicity because medium chain triglycerides (e.g., Miglyol 812 
N) and lecithins are already widely used in injectable preparations. Tween
®
 80 can also be 
ruled out in this toxicity because it is frequently used at high concentrations, e.g., 25% in 
docetaxel preparation without apparent toxicity (Strickley, 2004). Therefore, a compromise 385 
will have to be found between the toxicity of the excipient and the final concentration in 
fisetin. 
With regard to the physico-chemical properties of the fisetin nanoemulsion, it was 
found that the preparation containing Miglyol 812 N (No. 9) showed acceptable fisetin 
content, nanoparticle size and PDI. This fisetin nanoemulsion was found to be unstable at 390 
room temperature with increasing diameter and PDI values over time, with phase separation 
occurring on day 30. This relatively slow process could be explained by the Ostwald ripening 
in which larger particles grow at the expense of smaller ones due to the higher solubility of 
the smaller particles and to molecular diffusion through the continuous phase (Capek, 2004). 
This phenomenon finally ends up in the coalescence of the emulsion (Tadros et al., 2004). 395 
Because this phenomenon is temperature sensitive, it was noted that nanoemulsions kept at 
4°C were remarkably stable with almost unchanged particle diameter and PDI over the 30 day 
examination period. PDI smaller that 0.250 are considered acceptable for parenteral 
preparations (Müller et al., 2004). However, it was also noted, as expected, that the 
nanoemulsion was particularly unstable in steam sterilization conditions (121°C, 15 min) 400 
probably due to the non-ionic surface active agents which are not stable at high temperatures 
(Nornoo et al., 2008). To overcome this problem, sterilization by filtration could therefore be 
employed for nanoemulsions (Floyd, 1999). The formulated fisetin nanoemulsion presented a 
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negative zeta potential which is probably due to the anionic fractions of the employed lecithin 
(Wang et al., 2006).  405 
We have observed that fisetin nanoemulsion could exert its distinct morphological 
effects on endothelial cells similar to the free fisetin (Touil et al., 2009) indicating that fisetin 
could be released from its nanoemulsion formulation. These morphological changes on 
endothelial cells are attributed to a stabilization of the cytoskeleton as previously shown by 
increased acetylated alpha tubulin (Touil et al., 2009). 410 
Concerning the i.v. administration of the free fisetin and its nanoemulsion, we did not 
observe any pharmacokinetic difference, as expected for a classical emulsion, contrary to 
what is observed for a pegylated formulation which can increase the residence time (Reddy 
and Venkateswarlu, 2005). As a matter of fact, upon injection of a classical emulsion, the 
particles interact with the apolipoproteins and are captured by the reticulo-endothelial system 415 
leading to their rapid elimination from the blood compartment (Kawakami et al., 2000). One 
possibility to increase the residence time using the i.v. administration would be to pegylate the 
emulsion that could increase the surface hydrophilic properties by forming a steric barrier that 
could result in a longer retention time in plasma (Tamilvanan, 2004). 
We demonstrated that the i.p. administration of the fisetin nanoemulsion led to a 420 
significant improvement in bioavailability compared to the i.p. administration of the free 
fisetin, with a 24-fold increase in relative bioavailability compared to the free fisetin 
administered via the same route. This could be due to a faster absorption phase from the 
peritoneal cavity with the nanoemulsion compared to free fisetin. As a matter of fact, the 
mean absorption time was shorter with the nanoemulsion (2 h) compared to the free fisetin (6 425 
h). Similar results were reported for the hydrophobic taxoid paclitaxel where i.p. 
administration was leading to a significant improvement in bioavailability compared to the 
i.v. administration (Soma et al., 2009). In addition, this enhanced bioavailability of the fisetin 
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nanoemulsion is also probably resulting from the unique lymphatic distribution after i.p. 
administration which is a favourable property, especially with anticancer drugs that must 430 
access lymph nodes which are frequently harbouring metastases (Nishioka and Yoshino, 
2001).  
We also demonstrated that the fisetin nanoemulsion could elicit a significant 
antitumour activity in vivo in Lewis lung tumour bearing mice. It is noteworthy that a 
relatively low dose of the fisetin nanoemulsion corresponding to 36.6 mg/kg of fisetin was 435 
able to reduce by 53% the tumour volume, whereas a 6-fold higher dose (223 mg/kg) was 
required to obtain a similar tumour growth inhibition with the free fisetin, as recently reported 
by Touil et al. (Touil et al., 2011). This indicates that the nanoemulsion of fisetin is 
favourable to its anticancer action in vivo probably by increasing its bioavailability, as shown 
in this study. 440 
 
5. Conclusion 
 
In conclusion, we have developed a nanoemulsion of fisetin that allowed to solubilize 
a relatively high concentration of fisetin (5 mg/mL), thanks to the use of two surface active 445 
agents, i.e., Tween
®
 80 and Labrasol
®
. However the latter agent appeared to be relatively 
toxic when using the i.v. route, but was not found toxic by the i.p. route. The developed 
fisetin nanoemulsion could also markedly increase the bioavailability of fisetin after i.p. 
administration and was also found to significantly improve its antitumoral activity in tumour 
bearing mice compared to the free fisetin. The developed nanoemulsion of fisetin could 450 
therefore advantageously be employed to improve the antiangiogenic and anticancer activities 
of this flavonoid, as well as other flavonoids sharing the same problems of in vivo 
administration. 
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Table 1. Fisetin solubility in various solvents. 
Solvents 
Solubility 
mg/g 
Water < 1 
Ethanol < 14 
Long chain triglycerides  
Soybean oil < 1 
Carthame oil < 1 
Medium chain mono- di- or triglycerides  
Miglyol
®
 812 N (capric and caprylic acid triglycerides) < 1 
Captex
®
 355 (capric and caprylic acid triglycerides) < 1 
Labrafac Lipophile WL 1349
®
 (capric and caprylic acid triglycerides) < 1 
Imwitor
®
 742 (capric and caprylic mono- di- and triglycerides) < 4 
Short chain triglycerides: Triacetin (triester of glycerol and acetic acid) < 6 
Fatty acid esters: Ethyl oleate < 1 
Capmul
®
 PG8 (propylene glycol monocaprylate) < 5 
Capric acid < 1 
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Table 2. Fisetin solubility in various surfactants. 
Surfactants HLB
a 
Solubility 
mg/g 
Span
®
 85 (sorbitan trioleate) 1.8 < 2 
Labrafil M 1944 CS
®
 (glycerides and PEG 300 ester mixture) 4 < 3 
Capmul
®
 MCM (mono diglyceride of capric and caprylic acids) 5 < 7 
Vitamin E TPGS (α tocopheryl acid succinate ester/PEG 1000) 13 < 10 
Cremophor EL
®
 (polyethoxylated ricin oil) 13 < 26 
Myrj
®
 52 (polyoxyethylene glycol 2000 monostearate) 16.9 < 30 
Tween
®
 80 (polysorbate 80) 15 < 30 
Labrasol
®
 (caprylocaproyl polyoxyl-8 glycerides) 14 < 54 
 610 
a
 HLB, hydrophilic-lipophilic balance (a value <10 indicates a majority of lipophilic fractions 
and a value >10 indicates a majority of hydrophilic fractions). 
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Table 3. Fisetin solubility in various mixtures. 
Mixtures (in percent) 
Solubility 
mg/g 
Ethanol / Tween
®
 80 (2%) < 21 
Miglyol 812 N/ Tween® 80 ( 2%) < 1 
Soybean oil / Tween
®
 80 (15%) < 3 
Soybean oil / Span 85
®
 (10%)  < 1 
Miglyol
®
 812 N/ Span 85
®
 (7.5%) < 3 
Soybean oil / Labrasol
®
(50/50) ND
a 
Miglyol 812 N/ Labrasol®(50/50) ND
a 
Capmul MCM
®
 / Labrasol
®
 (50/50) < 21 
Tween
®
 80/ Labrasol
®
(20/80) < 45 
Tween
®
 80/ Labrasol
®
/ soybean oil (12/44/44) ND
a 
Tween
®
 80/ Labrasol
®
/ Miglyol
®
 812 N (12/44/44) < 30 
Mirj 52
®
/Solutol HS 15
®
/ Capmul MCM
®
 (57/29/14) < 24 
Tween
®
 80/ Labrasol
®
 / Capmul MCM
®
 (17/69/14) < 40 
 615 
a 
ND, not determined because the phases were not miscible in these proportions. 
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Table 4. Composition of the various emulsions. 
 Formulation number 
Component 1 2 3 4 5 6 7 8 9 10 
Soybean oil 10 10 20 - - - - 10 - - 
Miglyol
®
 812 N - - - 10 10 15 20 - 10 - 
Triacetin 10 - - - - - - - - - 
Capmul MCM
®
 - 10 - - - - - - - 6 
Labrasol
®
 - - 20 10 9.6 14.4 19.2 10 10 27 
Tween 80 2.5 2.5 - 2.5 0.4 0.6 0.8 2.5 2.5 7 
Lipoid E80
®
 1.2 1.2 - - - - - 1.2 1.2 - 
Water 76.3 76.3 60 77.5 80 70 60 76.3 76.3 60 
Observations NE 
a 
Lack of emulsification NE 
a 
Sol. 
b 
Fisetin incorporation 
on day 1 (mg/g) 
1  5 5 4 
 
a
 NE, nanoemulsion; 
b
 Sol., clear solution 620 
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Table 5. Fisetin nanoemulsion (preparation 9) stability parameters.  
 Day 
Parameter 0 1 4 7 15 30 
Diameter (nm) 20°C 153  2 a 189  1 331  7 749  54 2882  87 
Phase 
separation 
Diameter (nm) 4°C 138  5 138  0 152  4 144  2 147  2 154  2 
pH at 20°C 7.11  0.01 6.80  0.02 6.61  0.02 6.51  0.02 6.42  0.01 - 
pH at 4°C 7.09  0.01 6.79  0.02 6.81  0.02 6.65  0.03 N.D. 6.53  0.01 
Zeta potential () 20°C -28.4  0.6 -30.8  0.9 -34.8  1.4 -40.3  0.4 -39.9  0.5 - 
Zeta potential () 4°C -32.7  1.1 -26.7  1.0 -33.5  0.5 -34.7  1.6 -32.5  2.9 -34.1  2.5 
PDI
b
 20°C 0.129 0.090 0.201 0.371 1.000 - 
PDI
b
 4°C 0.151 0.157 0.136 0.128 0.147 0.115 
 
a
 Mean  SEM of 3 determinations; b PDI, polydispersity index. 
625 
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Table 6. Fisetin pharmacokinetic parameters after intravenous or intraperitoneal 
administration of free fisetin and fisetin nanoemulsion in mice (preparation 9). 
 Intravenous Intraperitoneal 
Parameter 
Free 
fisetin 
Fisetin 
Nano-
emulsion 
Free 
fisetin 
Fisetin 
Nano-
emulsion 
Dose (mg/kg) 13 13 223 112.5 
Cmax (µg/mL) 6.0 5.3 2.53 22.96 
Elimination constant (Kel) (h
-1
) 1.136 1.072 0.165 0.226 
Terminal half-life (h) 0.61 0.65 4.19 3.07 
AUC0→t (µg.h/mL) 1.12 1.13 4.07 48.53 
AUMC (µg.h²/mL) 1.09 1.12 28.26 143.56 
Mean residence time (MRT) (h) 0.97 0.99 6.95 2.96 
Mean absorption time (MAT) (h) - - 5.98 1.97 
Clearance (CL) (L/kg/h) 11.64 11.50 54.80 2.32 
Volume of distribution (Vss) (L/kg) 11.33 11.36 380.62 6.86 
Relative bioavailability 
a 
(Frel) - - 1 24 
 
a
 Frel = (AUC NE x dose FREE)/(AUC FREE x dose NE) 
 630 
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Figure captions 
 
Figure 1. Morphologic effects of fisetin on Eahy 926 endothelial cells after a 2 h exposure 
period. A, control with 1% DMSO; B, free fisetin (25 µg/mL); C, fisetin-free nanoemulsion 635 
(0.25%); D, fisetin nanoemulsion 12.5 µg/mL. Original magnification, 100X. 
 
Figure 2. Fisetin pharmacokinetics in mice after intravenous administration of free fisetin 
(dotted line) at 13 mg/kg, and after the intravenous administration of fisetin nanoemulsion at 
13 mg/kg (solid line). Error bars, SEM. 640 
 
Figure 3. Fisetin pharmacokinetics in mice after intraperitoneal administration of free fisetin 
(dotted line) at 223 mg/kg, and after intraperitoneal administration of fisetin nanoemulsion at 
112.5 mg/kg (solid line). Mean  SEM. 
 645 
Figure 4. Antitumour activity of the nanoemulsion of fisetin. Lewis carcinoma bearing mice 
received the fisetin nanoemulsion (NE Fisetin) by intraperitoneal injection at 18.3 and 36.6 
mg/kg for 12 consecutive days (indicated by arrows). Control mice received the 
nanoemulsion without fisetin (NE control). The asterisks represent a P value significant at 
0.05 (*), 0.01 (**) or 0.005 (***) level. Mean  SEM of 8 tumours per time point. 650 
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